The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

John C Lue - One of the best experts on this subject based on the ideXlab platform.

  • Levobunolol 0 5 and timolol 0 5 to prevent intraocular pressure elevation after neodymium yag laser posterior capsulotomy
    Journal of Cataract and Refractive Surgery, 1997
    Co-Authors: Sanford Rakofsky, Elaine P Kelley, Douglas D Koch, James D Faulkner, Stuart A Terry, Alan I Mandell, Ronald L Gross, Theresa L Iacono, John C Lue
    Abstract:

    Abstract Purpose: To evaluate the prophylactic effect of Levobunolol 0.5%, timolol 0.5%, or vehicle in reducing the incidence of postoperative intraocular pressure (IOP) spikes of 5 and 10 mm Hg or more in patients having neodymium:YAG (Nd:YAG) laser posterior capsulotomy. Setting: Miami Vision Center, Coral Gables, Florida; Cullen Eye Institute, Baylor College of Medicine, Houston, Texas; Cincinnati Eye Institute, Cincinnati, Ohio; South Texas Cataract and Glaucoma Center, San Antonio, Texas; Mid-South Eye Foundation, Memphis, Tennessee, USA. Methods: This prospective, double-masked, randomized study comprised 144 patients having Nd:YAG laser posterior capsulotomy in one eye. One drop of the test medication was administered preoperatively and one drop on the evening after surgery; IOP was measured preoperatively and 1, 2, 3, and 24 hours postoperatively. Results: Intraocular pressure elevations of 5 mm Hg or more were seen in 1 of 60 patients (2%) in the Levobunolol group, 4 of 54 (7%) in the timolol group, and 10 of 28 (36%) in the vehicle group. These elevations occurred significantly more frequently in the vehicle group than in the Levobunolol ( P P Conclusions: Levobunolol 0.5% or timolol 0.5% administered preoperatively and again in the evening after Nd:YAG laser capsulotomy effectively blunted the IOP rise that frequently follows laser surgery.

  • a comparison of the ocular hypotensive efficacy of twice daily 0 25 Levobunolol to 0 5 timolol in patients previously treated with 0 5 timolol
    Journal of Glaucoma, 1992
    Co-Authors: C C Beehler, John C Lue, William C Stewart, D K Macdonald, T A Croyle, C S Ostrov, E G Rosanelli, Alan S Crandall, T L Iacono, Elaine P Kelley
    Abstract:

    Treatment with noncardioselective beta-adrenoceptor antagonists (e.g., 0.5% timolol or 0.5% Levobunolol) is standard practice for lowering elevated intraocular pressure (IOP). However, because there are risks and side effects associated with the use of these agents, a lower, yet still effective, dose may be preferred. We gave 0.5% timolol twice daily for 30 days to 143 patients. In a double-masked, randomized fashion, we then assigned patients to continue to receive 0.5% timolol twice daily or 0.25% Levobunolol twice daily for 8 weeks. The mean unmedicated baseline IOP for both groups was approximately 25 mm Hg. After 30 days of timolol pretreatment, the mean IOP in both groups decreased to approximately 19 mm Hg (p = 0.210). After the 30-day timolol pretreatment period, and subsequent randomization to either 0.5% timolol or 0.25% Levobunolol treatment, there was little change in overall mean IOP (0.03 mm Hg decrease for Levobunolol, 0.06 mm Hg increase for timolol; p = 0.811) from the timolol pretreatment baseline. One patient assigned to the timolol treatment group was terminated from the study due to inadequate control of IOP. We conclude that the mean IOP lowering effect of 0.25% Levobunolol is equivalent to 0.5% timolol, and switching patients from twice-daily 0.5% timolol to twice-daily 0.25% Levobunolol poses no significant risk of decreased ocular hypotensive efficacy.

  • evaluation of once daily Levobunolol 0 25 and timolol 0 25 therapy for increased intraocular pressure
    American Journal of Ophthalmology, 1991
    Co-Authors: David E Silverstone, Elaine P Kelley, Thom J Zimmerman, Cdr Neil Choplin, Tom Mundorf, Aron D Rose, Jack F Stoecker, John C Lue
    Abstract:

    In a three-month, double-masked, randomized clinical trial, we evaluated the once-daily ocular hypotensive efficacy of 0.25% Levobunolol and 0.25% timolol in 80 patients with open-angle glaucoma or ocular hypertension. Thirty-seven of the 39 patients (95%) in the 0.25% Levobunolol group and 35 of the 41 patients (85%) in the 0.25% timolol group successfully completed the three-month study period. The overall mean decrease in intraocular pressure was 5.3 mm Hg (22%) in the 0.25% Levobunolol group and 5.4 mm Hg (22%) in the 0.25% timolol group. This difference was not statistically significant. In both treatment groups, effects on mean heart rate and blood pressure were minimal. The data suggest that Levobunolol 0.25% and timolol 0.25%, administered once dally, are equally effective in the treatment of open-angle glaucoma and ocular hypertension.

Elaine P Kelley - One of the best experts on this subject based on the ideXlab platform.

  • Levobunolol 0 5 and timolol 0 5 to prevent intraocular pressure elevation after neodymium yag laser posterior capsulotomy
    Journal of Cataract and Refractive Surgery, 1997
    Co-Authors: Sanford Rakofsky, Elaine P Kelley, Douglas D Koch, James D Faulkner, Stuart A Terry, Alan I Mandell, Ronald L Gross, Theresa L Iacono, John C Lue
    Abstract:

    Abstract Purpose: To evaluate the prophylactic effect of Levobunolol 0.5%, timolol 0.5%, or vehicle in reducing the incidence of postoperative intraocular pressure (IOP) spikes of 5 and 10 mm Hg or more in patients having neodymium:YAG (Nd:YAG) laser posterior capsulotomy. Setting: Miami Vision Center, Coral Gables, Florida; Cullen Eye Institute, Baylor College of Medicine, Houston, Texas; Cincinnati Eye Institute, Cincinnati, Ohio; South Texas Cataract and Glaucoma Center, San Antonio, Texas; Mid-South Eye Foundation, Memphis, Tennessee, USA. Methods: This prospective, double-masked, randomized study comprised 144 patients having Nd:YAG laser posterior capsulotomy in one eye. One drop of the test medication was administered preoperatively and one drop on the evening after surgery; IOP was measured preoperatively and 1, 2, 3, and 24 hours postoperatively. Results: Intraocular pressure elevations of 5 mm Hg or more were seen in 1 of 60 patients (2%) in the Levobunolol group, 4 of 54 (7%) in the timolol group, and 10 of 28 (36%) in the vehicle group. These elevations occurred significantly more frequently in the vehicle group than in the Levobunolol ( P P Conclusions: Levobunolol 0.5% or timolol 0.5% administered preoperatively and again in the evening after Nd:YAG laser capsulotomy effectively blunted the IOP rise that frequently follows laser surgery.

  • once daily versus twice daily Levobunolol 0 5 therapy a crossover study
    Ophthalmology, 1992
    Co-Authors: Robert J Derick, Gary D. Novack, Elaine P Kelley, Alan L Robin, Jack F Stoecker, James M Tielsch, Jeffrey L Wexler, Anne L Coleman
    Abstract:

    The authors executed a two-period, randomized, double-masked, crossover study comparing once-daily to twice-daily Levobunolol hydrochloride (0.5%) in 20 patients with elevated intraocular pressure (10P). Modified diurnal curves were performed at four times for each study arm: baseline, day 1, day 14, and day 28. The mean diurnal corrected decrease in 10P from baseline ranged from 16% ± 11 % to 22% ± 9% when the subjects were treated twice daily, and from 14% ± 10% to 18% ± 8% when the same subjects were treated once daily. At day 1, patients had a significantly greater 101? lowering after twice-daily therapy than after once-daily therapy ( P

  • a comparison of the ocular hypotensive efficacy of twice daily 0 25 Levobunolol to 0 5 timolol in patients previously treated with 0 5 timolol
    Journal of Glaucoma, 1992
    Co-Authors: C C Beehler, John C Lue, William C Stewart, D K Macdonald, T A Croyle, C S Ostrov, E G Rosanelli, Alan S Crandall, T L Iacono, Elaine P Kelley
    Abstract:

    Treatment with noncardioselective beta-adrenoceptor antagonists (e.g., 0.5% timolol or 0.5% Levobunolol) is standard practice for lowering elevated intraocular pressure (IOP). However, because there are risks and side effects associated with the use of these agents, a lower, yet still effective, dose may be preferred. We gave 0.5% timolol twice daily for 30 days to 143 patients. In a double-masked, randomized fashion, we then assigned patients to continue to receive 0.5% timolol twice daily or 0.25% Levobunolol twice daily for 8 weeks. The mean unmedicated baseline IOP for both groups was approximately 25 mm Hg. After 30 days of timolol pretreatment, the mean IOP in both groups decreased to approximately 19 mm Hg (p = 0.210). After the 30-day timolol pretreatment period, and subsequent randomization to either 0.5% timolol or 0.25% Levobunolol treatment, there was little change in overall mean IOP (0.03 mm Hg decrease for Levobunolol, 0.06 mm Hg increase for timolol; p = 0.811) from the timolol pretreatment baseline. One patient assigned to the timolol treatment group was terminated from the study due to inadequate control of IOP. We conclude that the mean IOP lowering effect of 0.25% Levobunolol is equivalent to 0.5% timolol, and switching patients from twice-daily 0.5% timolol to twice-daily 0.25% Levobunolol poses no significant risk of decreased ocular hypotensive efficacy.

  • evaluation of once daily Levobunolol 0 25 and timolol 0 25 therapy for increased intraocular pressure
    American Journal of Ophthalmology, 1991
    Co-Authors: David E Silverstone, Elaine P Kelley, Thom J Zimmerman, Cdr Neil Choplin, Tom Mundorf, Aron D Rose, Jack F Stoecker, John C Lue
    Abstract:

    In a three-month, double-masked, randomized clinical trial, we evaluated the once-daily ocular hypotensive efficacy of 0.25% Levobunolol and 0.25% timolol in 80 patients with open-angle glaucoma or ocular hypertension. Thirty-seven of the 39 patients (95%) in the 0.25% Levobunolol group and 35 of the 41 patients (85%) in the 0.25% timolol group successfully completed the three-month study period. The overall mean decrease in intraocular pressure was 5.3 mm Hg (22%) in the 0.25% Levobunolol group and 5.4 mm Hg (22%) in the 0.25% timolol group. This difference was not statistically significant. In both treatment groups, effects on mean heart rate and blood pressure were minimal. The data suggest that Levobunolol 0.25% and timolol 0.25%, administered once dally, are equally effective in the treatment of open-angle glaucoma and ocular hypertension.

David Hartenbaum - One of the best experts on this subject based on the ideXlab platform.

  • a comparison of the efficacy and tolerability of 0 5 timolol maleate ophthalmic gel forming solution qd and 0 5 Levobunolol hydrochloride bid in patients with ocular hypertension or open angle glaucoma
    Journal of Ocular Pharmacology and Therapeutics, 2002
    Co-Authors: Lee K Halper, Lisa Johnsonpratt, Thomas Dobbins, David Hartenbaum
    Abstract:

    The purpose of this study was to compare the ocular hypotensive efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution (timolol gel) and 0.5% Levobunolol hydrochloride (Levobunolol). This was a randomized, double-masked, multicenter, active-controlled, 2-period, crossover study. After a 3-week, single-masked placebo run-in phase, patients with ocular hypertension or open-angle glaucoma and an intraocular pressure (IOP) ≥ 22 mmHg were randomized to receive timolol gel QD or Levobunolol BID for 6 weeks followed by a 3-week, placebo washout period. Patients were then crossed over to the alternate treatment for 6 weeks. IOP and heart rate (HR) were measured at 3 and 6 weeks after the start of therapy with either timolol gel or Levobunolol. Of 133 patients randomized, 116 received both treatments. Timolol gel QD was comparable to Levobunolol BID in reducing trough and peak IOP. At trough, HR was marginally increased with timolol gel and was decreased with Levobunolol (p = <0.001). At...

  • Efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD compared with 0.5% Levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension
    Clinical therapeutics, 1998
    Co-Authors: Thomas R. Walters, Susan Maloney, Deborah Slater, Charlie Liss, Helene M. Wilson, David Hartenbaum
    Abstract:

    We compared the efficacy of timolol maleate ophthalmic gel-forming solution 0.5% QD with that of Levobunolol hydrochloride 0.5% BID, as measured by change in intraocular pressure (IOP), effect on heart rate, and ocular tolerability. The study had a positive-controlled, double-masked, randomized, multicenter, 12-week, two-period (6 weeks each), crossover design. One hundred fifty-two patients with open-angle glaucoma or ocular hypertension were randomized to receive either timolol maleate gel-forming solution QD or Levobunolol BID for 6 weeks, followed by a crossover to the alternate treatment. IOP and heart rate were measured at morning trough and peak during weeks 3, 6, 9, and 12. Timolol maleate gel-forming solution QD was comparable to Levobunolol BID in reducing IOP at peak and trough. Although the effects on peak heart rate were similar between the two medications, the effect on trough heart rate of timolol maleate gel-forming solution QD was significantly less than that of Levobunolol BID (P = 0.001). The incidence of ocular burning and stinging was comparable between the two treatments. Patients experienced significantly more blurred vision when using timolol maleate gel-forming solution than when using Levobunolol (P = 0.013). Overall, more patients experienced at least one adverse event when using timolol maleate gel-forming solution. Timolol maleate gel-forming solution QD is as efficacious in reducing IOP as Levobunolol BID.

Sanford Rakofsky - One of the best experts on this subject based on the ideXlab platform.

  • Levobunolol 0 5 and timolol 0 5 to prevent intraocular pressure elevation after neodymium yag laser posterior capsulotomy
    Journal of Cataract and Refractive Surgery, 1997
    Co-Authors: Sanford Rakofsky, Elaine P Kelley, Douglas D Koch, James D Faulkner, Stuart A Terry, Alan I Mandell, Ronald L Gross, Theresa L Iacono, John C Lue
    Abstract:

    Abstract Purpose: To evaluate the prophylactic effect of Levobunolol 0.5%, timolol 0.5%, or vehicle in reducing the incidence of postoperative intraocular pressure (IOP) spikes of 5 and 10 mm Hg or more in patients having neodymium:YAG (Nd:YAG) laser posterior capsulotomy. Setting: Miami Vision Center, Coral Gables, Florida; Cullen Eye Institute, Baylor College of Medicine, Houston, Texas; Cincinnati Eye Institute, Cincinnati, Ohio; South Texas Cataract and Glaucoma Center, San Antonio, Texas; Mid-South Eye Foundation, Memphis, Tennessee, USA. Methods: This prospective, double-masked, randomized study comprised 144 patients having Nd:YAG laser posterior capsulotomy in one eye. One drop of the test medication was administered preoperatively and one drop on the evening after surgery; IOP was measured preoperatively and 1, 2, 3, and 24 hours postoperatively. Results: Intraocular pressure elevations of 5 mm Hg or more were seen in 1 of 60 patients (2%) in the Levobunolol group, 4 of 54 (7%) in the timolol group, and 10 of 28 (36%) in the vehicle group. These elevations occurred significantly more frequently in the vehicle group than in the Levobunolol ( P P Conclusions: Levobunolol 0.5% or timolol 0.5% administered preoperatively and again in the evening after Nd:YAG laser capsulotomy effectively blunted the IOP rise that frequently follows laser surgery.

Jack F Stoecker - One of the best experts on this subject based on the ideXlab platform.

  • once daily versus twice daily Levobunolol 0 5 therapy a crossover study
    Ophthalmology, 1992
    Co-Authors: Robert J Derick, Gary D. Novack, Elaine P Kelley, Alan L Robin, Jack F Stoecker, James M Tielsch, Jeffrey L Wexler, Anne L Coleman
    Abstract:

    The authors executed a two-period, randomized, double-masked, crossover study comparing once-daily to twice-daily Levobunolol hydrochloride (0.5%) in 20 patients with elevated intraocular pressure (10P). Modified diurnal curves were performed at four times for each study arm: baseline, day 1, day 14, and day 28. The mean diurnal corrected decrease in 10P from baseline ranged from 16% ± 11 % to 22% ± 9% when the subjects were treated twice daily, and from 14% ± 10% to 18% ± 8% when the same subjects were treated once daily. At day 1, patients had a significantly greater 101? lowering after twice-daily therapy than after once-daily therapy ( P

  • evaluation of once daily Levobunolol 0 25 and timolol 0 25 therapy for increased intraocular pressure
    American Journal of Ophthalmology, 1991
    Co-Authors: David E Silverstone, Elaine P Kelley, Thom J Zimmerman, Cdr Neil Choplin, Tom Mundorf, Aron D Rose, Jack F Stoecker, John C Lue
    Abstract:

    In a three-month, double-masked, randomized clinical trial, we evaluated the once-daily ocular hypotensive efficacy of 0.25% Levobunolol and 0.25% timolol in 80 patients with open-angle glaucoma or ocular hypertension. Thirty-seven of the 39 patients (95%) in the 0.25% Levobunolol group and 35 of the 41 patients (85%) in the 0.25% timolol group successfully completed the three-month study period. The overall mean decrease in intraocular pressure was 5.3 mm Hg (22%) in the 0.25% Levobunolol group and 5.4 mm Hg (22%) in the 0.25% timolol group. This difference was not statistically significant. In both treatment groups, effects on mean heart rate and blood pressure were minimal. The data suggest that Levobunolol 0.25% and timolol 0.25%, administered once dally, are equally effective in the treatment of open-angle glaucoma and ocular hypertension.